Zydus Wellness has appointed Adhir Anand as head – media and digital. He joins the health and wellness company after working with Wavemaker for 7 years, where most recently he was working as general ...

Mumbai: Zydus Wellness is leaning into growth across nutrition and personal care, with its latest investor presentation revealing sharp revenue gains and an aggressive push into new categories and ...

Sentynl Therapeutics licenses Progerinin from PRG S&T for Hutchinson-Gilford Progeria Syndrome. Clinical trial data expected ...

Zydus Lifesciences said its Desidustat tablets, licensed to a subsidiary of China Medical System Holdings (CMS), have been approved in China for treating renal anaemia by the National Medical Products ...

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products ...

Ahmedabad: China's National Medical Products Administration has approved Desidustat tablets for treating renal anaemia in ...

Zydus Wellness share price jumps 16% on heavy volumes after strong Q3 results; brokerages see recovery in organic growth and maintain 'Buy' rating.

Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has licensed the experimental molecule Progerinin to treat ...

Zydus Lifesciences has received approval from China's NMPA for its innovative Desidustat tablets meant for treating renal anaemia. Licensed to a China Medical System subsidiary, the drug addresses ...

Stocks including RIL, Adani Enterprises, Tata Motors, RVNL, Sun Pharma, LTTS, Zydus Life, GMDC, Power Mech, NOCIL and more will be in the spotlight on Tuesday, March 17.

Zydus Lifesciences’ anaemia drug Desidustat receives NMPA approval in China, targeting non-dialysis CKD patients.